|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Inclusion Criteria | Javelin | | MPDL3280A | Study 1108 | CheckMate 032 | Cohort 2 | CheckMate 275 | KeyNote 045 | IMvigor 211 |
| Age ≥ 18 years | X | | X | X | X | X | X | X | X |
| ECOG ≤1 | X | | X | X | X | X | X |  | X |
| Urothelial histology | X | | X | X | X | X | X | X | X |
| Cisplatin eligible patients required treatment with at least 1 prior platinum-based chemotherapy\* | X | |  |  | X | X | X | X | X |
| No limit to lines of prior chemotherapy | X | | X | X | X | X | X |  |  |
| Prior treatment with PD-1/PD-L1 CPI excluded | X | |  | X | X |  | X | X | X |
| Active brain or leptomeningal metastasis excluded | X | | X | X | X | X | X | X | X |
| Excluded active autoimmune disease | X | | X | X | X | X | X | X | X |
|  | |